ATx201
Phase 2Small molecule
ATx201 is one of 34 small molecule programs targeting Impetigo. It is currently in Phase 2.
2
Indications
6
Total Trials
0
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Celestone
SSchering-Plough
Phase 3
Calcineurin Inhibitors
SanofiPhase 3
Elidel
BayerPhase 3
LNK01001
LLynk Pharmaceuticals Co., Ltd
Phase 3
Benvitimod
PPeking University People's Hospital
Phase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
Prograf
VVeloxis Pharmaceuticals
Preclinical
Stapokibatrt
KKeymed Biosciences Co.Ltd
Phase 3
MSRD-100
MMerz North America, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Impetigo1 trial
Atopic Dermatitis1 trial
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ATx201. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUNION therapeutics